Several clinical studies have proven that treatment with monoclonal antibodies to IL-6R improves symptoms of rheumatoid arthritis, Castleman’s disease and systemic juvenile idiopathic arthritis (Hunter and Jones 2015). This evidence concerns the gene IL6R and rheumatoid arthritis.